[Skip to Content]
[Skip to Content Landing]

Incidence of Multisystem Inflammatory Syndrome in Children Among US Persons Infected With SARS-CoV-2

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  What was the incidence of multisystem inflammatory syndrome in children (MIS-C) among persons with SARS-CoV-2 infection in the US during April to June 2020?

Findings  In this cohort study of 248 persons with MIS-C, MIS-C incidence was 5.1 persons per 1 000 000 person-months and 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. Incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons compared with White persons and in younger persons compared with older persons.

Meaning  These findings suggest that MIS-C was a rare complication of SARS-CoV-2 infection; further study is needed to understand why MIS-C incidence varied by race/ethnicity and age group.

Abstract

Importance  Multisystem inflammatory syndrome in children (MIS-C) is associated with recent or current SARS-CoV-2 infection. Information on MIS-C incidence is limited.

Objective  To estimate population-based MIS-C incidence per 1 000 000 person-months and to estimate MIS-C incidence per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years.

Design, Setting, and Participants  This cohort study used enhanced surveillance data to identify persons with MIS-C during April to June 2020, in 7 jurisdictions reporting to both the Centers for Disease Control and Prevention national surveillance and to Overcoming COVID-19, a multicenter MIS-C study. Denominators for population-based estimates were derived from census estimates; denominators for incidence per 1 000 000 SARS-CoV-2 infections were estimated by applying published age- and month-specific multipliers accounting for underdetection of reported COVID-19 case counts. Jurisdictions included Connecticut, Georgia, Massachusetts, Michigan, New Jersey, New York (excluding New York City), and Pennsylvania. Data analyses were conducted from August to December 2020.

Exposures  Race/ethnicity, sex, and age group (ie, ≤5, 6-10, 11-15, and 16-20 years).

Main Outcomes and Measures  Overall and stratum-specific adjusted estimated MIS-C incidence per 1 000 000 person-months and per 1 000 000 SARS-CoV-2 infections.

Results  In the 7 jurisdictions examined, 248 persons with MIS-C were reported (median [interquartile range] age, 8 [4-13] years; 133 [53.6%] male; 96 persons [38.7%] were Hispanic or Latino; 75 persons [30.2%] were Black). The incidence of MIS-C per 1 000 000 person-months was 5.1 (95% CI, 4.5-5.8) persons. Compared with White persons, incidence per 1 000 000 person-months was higher among Black persons (adjusted incidence rate ratio [aIRR], 9.26 [95% CI, 6.15-13.93]), Hispanic or Latino persons (aIRR, 8.92 [95% CI, 6.00-13.26]), and Asian or Pacific Islander (aIRR, 2.94 [95% CI, 1.49-5.82]) persons. MIS-C incidence per 1 000 000 SARS-CoV-2 infections was 316 (95% CI, 278-357) persons and was higher among Black (aIRR, 5.62 [95% CI, 3.68-8.60]), Hispanic or Latino (aIRR, 4.26 [95% CI, 2.85-6.38]), and Asian or Pacific Islander persons (aIRR, 2.88 [95% CI, 1.42-5.83]) compared with White persons. For both analyses, incidence was highest among children aged 5 years or younger (4.9 [95% CI, 3.7-6.6] children per 1 000 000 person-months) and children aged 6 to 10 years (6.3 [95% CI, 4.8-8.3] children per 1 000 000 person-months).

Conclusions and Relevance  In this cohort study, MIS-C was a rare complication associated with SARS-CoV-2 infection. Estimates for population-based incidence and incidence among persons with infection were higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons. Further study is needed to understand variability by race/ethnicity and age group.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Accepted for Publication: May 4, 2021.

Published: June 10, 2021. doi:10.1001/jamanetworkopen.2021.16420

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Payne AB et al. JAMA Network Open.

Corresponding Author: Angela P. Campbell, MD, MPH, COVID-19 Response Team, Centers for Disease Control and Prevention, 1600 Clifton Rd NE, MS H24-5, Atlanta, GA 30329 (app4@cdc.gov).

Author Contributions: Drs Payne and Campbell had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Payne, Gilani, Randolph, Dufort, Maxted, Edison, Kleinman, Hoots, Reed, Curns, Langley, Campbell, Flori.

Acquisition, analysis, or interpretation of data: Payne, Gilani, Godfred-Cato, Belay, Feldstein, Patel, Randolph, Newhams, D. Thomas, Magleby, Hsu, Burns, Dufort, Maxted, Pietrowski, Longenberger, Bidol, Henderson, Sosa, Edmundson, Tobin-D'Angelo, Heidemann, Singh, Giuliano, Kleinman, Tarquinio, Walsh, Fitzgerald, Clouser, Gertz, R. W. Carroll, C. L. Carroll, Hoots, Reed, Dahlgren, Oster, Pierce, Curns, Campbell, Balachandran, Murray, Burkholder, Brancard, Lifshitz, Leach, Charpie, Tice, Coffin, Perella, Jones, Marohn, Yager, Fernandes, Flori, Koncicki, Walker, Di Pentima, Li, Horwitz, Gaur, Coffey, Harwayne-Gidansky, Hymes, N. J. Thomas, Ackerman, Cholette.

Drafting of the manuscript: Payne, Gilani, Singh, Pierce, Campbell, Harwayne-Gidansky.

Critical revision of the manuscript for important intellectual content: Payne, Gilani, Godfred-Cato, Belay, Feldstein, Patel, Randolph, Newhams, D. Thomas, Magleby, Hsu, Burns, Dufort, Maxted, Pietrowski, Longenberger, Bidol, Henderson, Sosa, Edmundson, Tobin-D'Angelo, Edison, Heidemann, Singh, Giuliano, Kleinman, Tarquinio, Walsh, Fitzgerald, Clouser, Gertz, R. W. Carroll, C. L. Carroll, Hoots, Reed, Dahlgren, Oster, Curns, Langley, Campbell, Balachandran, Murray, Burkholder, Brancard, Lifshitz, Leach, Charpie, Tice, Coffin, Perella, Jones, Marohn, Yager, Fernandes, Flori, Koncicki, Walker, Di Pentima, Li, Horwitz, Gaur, Coffey, Harwayne-Gidansky, Hymes, N. J. Thomas, Ackerman, Cholette.

Statistical analysis: Payne, Magleby, Sosa, Reed, Dahlgren, Brancard, Leach, Charpie, Tice, Perella.

Obtained funding: Randolph, Walsh.

Administrative, technical, or material support: Gilani, Godfred-Cato, Feldstein, Patel, Randolph, Newhams, D. Thomas, Henderson, Fitzgerald, Gertz, R. W. Carroll, C. L. Carroll, Hoots, Oster, Curns, Campbell, Balachandran, Murray, Burkholder, Tice, Coffin, Perella, Yager, Fernandes, Flori, Di Pentima, Gaur, Hymes.

Supervision: Belay, Randolph, Edison, Singh, Giuliano, Kleinman, Gertz, Hoots, Langley, Campbell, Coffin, Perella, N. J. Thomas.

Conflict of Interest Disclosures: Dr Randolph reported receiving grants from the Centers for Disease Control and Prevention (CDC) during the conduct of this study and personal fees from UpToDate and serving as a scientific advisor for LaJolla Pharma outside the submitted work. Ms Newhams reported receiving grants from the CDC during the conduct of the study. Ms Bidol reported receiving grants from the CDC during the conduct of the study. Mr Henderson reported receiving grants from the CDC during the conduct of this study. Dr Heidemann reported grants from NIH during the conduct of the study. Dr Singh reported grants from CDC during the conduct of the study. Dr Giuliano reported receiving grants from the CDC during the conduct of the study. Dr Kleinman reported receiving grants from the CDC during the conduct of the study and owning stock in Regeneron, GlaxoSmithKline, Sanofi, Amgen. Dr Tarquinio reported receiving grants from the CDC. Dr Walsh reported receiving grants from the CDC during the conduct of the study. Dr Fitzgerald receiving reported grants from the CDC and National Institute of Diabetes and Digestive and Kidney Diseases during the conduct of the study. Dr Gertz reported receiving grants from the CDC during the conduct of the study. Dr R. W. Carroll reported receiving personal fees from EDCTP and Unitaid outside the submitted work. Dr Coffin reported receiving grants from and serving on a data and safety monitoring board for Merck & Co. and serving as a consultant for Genentech outside the submitted work. Ms Perella reported receiving grants from the CDC outside the submitted work. Ms Jones reported receiving grants from CDC during the conduct of the study. Dr Flori reported receiving grants from the National Heart, Lung and Blood Institute and Eunice Kennedy Shriver National Institute of Child Health and Human Development, serving on committees for the Society for Critical Care Medicine Sepsis, Michigan Thoracic Society, and Pediatric Acute Lung Injury and Sepsis Investigators Network outside the submitted work. Dr N. J. Thomas reported receiving grants from the CDC during the conduct of the study. No other disclosures were reported.

Funding/Support: The Overcoming COVID-19 study was funded by the CDC under a contract to Boston Children’s Hospital. All participating jurisdictions received financial support from the CDC Prevention through the Epidemiology and Laboratory Capacity for Prevention and Control of Emerging Infectious Diseases cooperative agreement.

Role of the Funder/Sponsor: The funder participated in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.

MIS-C Incidence Authorship Group: Neha Balachandran, MBBS, MPH; Thomas S. Murray, MD, PhD; Cole Burkholder, MPH; Troy Brancard, MPH; Jenna Lifshitz; Dylan Leach, MPH; Ian Charpie, MPH; Cory Tice, MPH; Susan E. Coffin, MD, MPH; Dana Perella, MPH; Kaitlin Jones, RN; Kimberly L. Marohn, MD; Phoebe H. Yager, MD; Neil D. Fernandes, MBBS; Heidi R. Flori, MD; Monica L. Koncicki, MD; Karen S. Walker, MD; Maria Cecilia Di Pentima, MD; Simon Li, MD, MPH; Steven M. Horwitz, MD; Sunanda Gaur, MD; Dennis C. Coffey, MD; Ilana Harwayne-Gidansky, MD; Saul R. Hymes, MD; Neal J. Thomas, MD, MSc; Kate G. Ackerman, MD, MPH; Jill M. Cholette, MD.

Affiliations of MIS-C Incidence Authorship Group: COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, Georgia (Balachandran); New Jersey Department of Health, Trenton (Brancard, Lifshitz); Massachusetts Department of Health, Boston (Leach, Charpie); New York State Department of Health, Albany (Tice); Philadelphia Department of Public Health, Philadelphia, Pennsylvania (Coffin, Perella); Michigan Department of Health and Human Services, Lansing (Burkholder); Department of Pediatrics, Infectious Disease and Global Health, Yale School of Medicine, New Haven, Connecticut (Murray); Emory University School of Medicine, Children’s Healthcare of Atlanta, Atlanta, Georgia (Jones); Baystate Children’s Hospital, Springfield, Massachusetts (Marohn); MassGeneral Hospital for Children, Harvard Medical School, Boston, Massachusetts (Yager, Fernandes); University of Michigan CS Mott Children’s Hospital, Ann Arbor (Flori); St Christopher’s Hospital for Children, Philadelphia, Pennsylvania (Koncicki); Cooper University Hospital, Camden, New Jersey (Walker); Goryeb Children’s Hospital, Morristown, New Jersey (Di Pentima); Bristol-Myers Squibb Children’s Hospital, New Brunswick, New Jersey (Li, Horwitz, Gaur); The Valley Hospital, Ridgewood, New Jersey (Coffey); Stony Brook University Hospital, Stony Brook, New York (Harwayne-Gidansky, Hymes); Penn State Children’s Hospital, Hershey, Pennsylvania (Thomas); Golisano Children’s Hospital, Rochester, New York (Ackerman, Cholette).

Disclaimer: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention.

Additional Contributions: Jihong Yao, MEng (New Jersey Department of Health); Stella Tsai, PhD (New Jersey Department of Health); Wendy Pulver, MS (New York State Department of Health); Debra Blog, MD (New York State Department of Health); Elina Paul, MPH (Children’s Hospital of Philadelphia); Patricia Hennessey, RN, BSN, MSN (St. Christopher’s Hospital for Children); Bryce Spiker, MPH (Michigan Department of Health and Human Services); Libby Reeg, MPH (Michigan Department of Health and Human Services); Tiffany Henderson, MPH (Michigan Department of Health and Human Services); Makayla Murphy, BA (Connecticut Children’s); Juan C. Salazar, MD, MPH (Connecticut Children’s); Kathy Krechevsky, MT (Yale-New Haven Hospital); Christina Murdzek, MHS (Yale-New Haven Hospital); Siri Wilson, MPH (Georgia Department of Public Health); Kristina Lam, MD, MPH (Georgia Department of Public Health); John Olmstead, MPH (Georgia Department of Public Health; Council of State and Territorial Epidemiologists) assisted in data collection for this study. These individuals were not compensated for this work beyond their usual salaries.

References
1.
Dong  Y , Mo  X , Hu  Y ,  et al.  Epidemiology of COVID-19 among children in China.   Pediatrics. 2020;145(6):e20200702. doi:10.1542/peds.2020-0702PubMedGoogle Scholar
2.
Garg  S , Kim  L , Whitaker  M ,  et al.  Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1-30, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464. doi:10.15585/mmwr.mm6915e3PubMedGoogle ScholarCrossref
3.
CDC COVID-19 Response Team.  Coronavirus disease 2019 in children—United States, February 12-April 2, 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(14):422-426. doi:10.15585/mmwr.mm6914e4PubMedGoogle ScholarCrossref
4.
Zhou  F , Yu  T , Du  R ,  et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.   Lancet. 2020;395(10229):1054-1062. doi:10.1016/S0140-6736(20)30566-3PubMedGoogle ScholarCrossref
5.
Dufort  EM , Koumans  EH , Chow  EJ ,  et al; New York State and Centers for Disease Control and Prevention Multisystem Inflammatory Syndrome in Children Investigation Team.  Multisystem inflammatory syndrome in children in New York state.   N Engl J Med. 2020;383(4):347-358. doi:10.1056/NEJMoa2021756PubMedGoogle ScholarCrossref
6.
Feldstein  LR , Rose  EB , Randolph  AG .  Multisystem inflammatory syndrome in children in the United States—reply.   N Engl J Med. 2020;383(18):1794-1795. doi:10.1056/NEJMc2026136PubMedGoogle Scholar
7.
Jones  VG , Mills  M , Suarez  D ,  et al.  COVID-19 and Kawasaki disease: novel virus and novel case.   Hosp Pediatr. 2020;10(6):537-540. doi:10.1542/hpeds.2020-0123PubMedGoogle ScholarCrossref
8.
Reese  H , Iuliano  AD , Patel  NN ,  et al.  Estimated incidence of COVID-19 illness and hospitalization—United States, February-September, 2020.   Clin Infect Dis. 2020;ciaa1780. doi:10.1093/cid/ciaa1780PubMedGoogle Scholar
9.
Verdoni  L , Mazza  A , Gervasoni  A ,  et al.  An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study.   Lancet. 2020;395(10239):1771-1778. doi:10.1016/S0140-6736(20)31103-XPubMedGoogle ScholarCrossref
10.
Ouldali  N , Yang  DD , Madhi  F ,  et al; investigator group of the PANDOR study.  Factors associated with severe SARS-CoV-2 infection.   Pediatrics. 2021;147(3):e2020023432. doi:10.1542/peds.2020-023432PubMedGoogle Scholar
11.
Centers for Disease Control and Prevention. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19). News release. CDC Health Alert Network. May 14, 2020. Accessed November 1, 2020. https://emergency.cdc.gov/han/2020/han00432.asp
12.
Belot  A , Antona  D , Renolleau  S ,  et al.  SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May 2020.   Euro Surveill. 2020;25(22). doi:10.2807/1560-7917.ES.2020.25.22.2001010PubMedGoogle Scholar
13.
Cheung  EW , Zachariah  P , Gorelik  M ,  et al.  Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York City.   JAMA. 2020;324(3):294-296. doi:10.1001/jama.2020.10374PubMedGoogle ScholarCrossref
14.
Chiotos  K , Bassiri  H , Behrens  EM ,  et al.  Multisystem inflammatory syndrome in children during the coronavirus 2019 pandemic: a case series.   J Pediatric Infect Dis Soc. 2020;9(3):393-398. doi:10.1093/jpids/piaa069PubMedGoogle ScholarCrossref
15.
Feldstein  LR , Rose  EB , Horwitz  SM ,  et al; Overcoming COVID-19 Investigators; CDC COVID-19 Response Team.  Multisystem inflammatory syndrome in U.S. children and adolescents.   N Engl J Med. 2020;383(4):334-346. doi:10.1056/NEJMoa2021680PubMedGoogle ScholarCrossref
16.
Godfred-Cato  S , Bryant  B , Leung  J ,  et al; California MIS-C Response Team.  COVID-19-associated multisystem inflammatory syndrome in children—United States, March-July 2020.   MMWR Morb Mortal Wkly Rep. 2020;69(32):1074-1080. doi:10.15585/mmwr.mm6932e2PubMedGoogle ScholarCrossref
17.
Toubiana  J , Poirault  C , Corsia  A ,  et al.  Kawasaki-like multisystem inflammatory syndrome in children during the COVID-19 pandemic in Paris, France: prospective observational study.   BMJ. 2020;369:m2094. doi:10.1136/bmj.m2094PubMedGoogle ScholarCrossref
18.
Lee  EH , Kepler  KL , Geevarughese  A ,  et al.  Race/ethnicity among children with COVID-19-associated multisystem inflammatory syndrome.   JAMA Netw Open. 2020;3(11):e2030280. doi:10.1001/jamanetworkopen.2020.30280PubMedGoogle Scholar
19.
Abrams  JY , Godfred-Cato  SE , Oster  ME ,  et al.  Multisystem inflammatory syndrome in children associated with severe acute respiratory syndrome coronavirus 2: a systematic review.   J Pediatr. 2020;226:45-54.e1. doi:10.1016/j.jpeds.2020.08.003PubMedGoogle ScholarCrossref
20.
Centers for Disease Control and Prevention. Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C). Accessed November 1, 2020. https://www.cdc.gov/mis-c/hcp/
21.
Centers for Disease Control and Prevention. Bridged-race population estimates 1990-2019. Accessed November 3, 2020. https://wonder.cdc.gov/bridged-race-v2019.html
22.
Kleinbaum  DG , Kupper  LL , Nizam  A , Muller  KE .  Applied Regression Analysis and Other Multivariable Methods. 4th ed. Duxberry Press; 2007.
23.
Rubin  DB .  Multiple Imputation for Nonresponse in Surveys. John Wiley & Sons; 2004.
24.
Maddox  RA , Person  MK , Kennedy  JL ,  et al.  Kawasaki disease and Kawasaki disease shock syndrome hospitalization rates in the United States, 2006-2018.   Pediatr Infect Dis J. 2021;40(4):284-288. doi:10.1097/INF.0000000000002982PubMedGoogle ScholarCrossref
25.
Duarte-Salles  T , Vizcaya  D , Pistillo  A ,  et al  Baseline characteristics, management, and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and 1,952,693 with influenza in France, Germany, Spain, South Korea and the United States: an international network cohort study.   medRxiv. Preprint posted online October 30, 2020. doi:10.1101/2020.10.29.20222083Google Scholar
26.
Brennan Ramirez  LK , Baker  EA , Metzler  M .  Promoting Health Equity: A Resource to Help Communities Address Social Determinants of Health. Department of Health and Human Services; Centers for Disease Control and Prevention; 2008.
27.
Centers for Disease Control and Prevention. COVID-19 response health equity strategy: accelerating progress towards reducing COVID-19 disparities and achieving health equity. Updated August 21, 2020. Accessed January 19, 2021. https://www.cdc.gov/coronavirus/2019-ncov/community/health-equity/cdc-strategy.html
28.
Centers for Disease Control and Prevention. Risk for COVID-19 infection, hospitalization, and death by race/ethnicity. Updated November 30, 2020. Accessed January 9, 2021. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html
29.
Belay  ED , Abrams  J , Oster  ME ,  et al.  Trends in geographic and temporal distribution of US children with multisystem inflammatory syndrome during the COVID-19 pandemic.   JAMA Pediatr. Published online April 6, 2021. doi:10.1001/jamapediatrics.2021.0630PubMedGoogle Scholar
AMA CME Accreditation Information

Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00  AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.00 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program;;
  • 1.00 Self-Assessment points in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program;
  • 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program;
  • 1.00 Lifelong Learning points in the American Board of Pathology’s (ABPath) Continuing Certification program; and
  • 1.00 credit toward the CME [and Self-Assessment requirements] of the American Board of Surgery’s Continuous Certification program

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.

Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
Want full access to the AMA Ed Hub?
After you sign up for AMA Membership, make sure you sign in or create a Physician account with the AMA in order to access all learning activities on the AMA Ed Hub
Buy this activity
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Close
Close

Lookup An Activity

or

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close